Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 11/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891083 | 1.00 | DUT (0.45) | DUTPKMALDH1A1LMNACRBN | |
| SCHEMBL807972 | 0.79 | DUT (0.44) | DUTPKMALDH1A1LMNACRBN | |
| SCHEMBL807971 | 0.79 | DUT (0.44) | DUTPKMALDH1A1LMNACRBN | |
| SCHEMBL9891081 | 0.79 | TK1 (0.52) | — | |
| SCHEMBL9891082 | 0.79 | TK1 (0.52) | — | |
| SCHEMBL9891089 | 0.78 | TK1 (0.38) | ALDH1A1 | |
| SCHEMBL9891086 | 0.78 | LMNA (0.38) | LMNA | |
| SCHEMBL9891087 | 0.78 | TK1 (0.38) | — | |
| SCHEMBL9891088 | 0.78 | TK1 (0.38) | — | |
| SCHEMBL9891085 | 0.78 | LMNA (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785629-B2 | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20120142897-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | UNIVERSITE D'ORLEANS (FR) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142897-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | PNP, PHPT1, TYMP | DUT 179/4885PKM 262/4885ALDH1A1 3189/4885 |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | PNP, TYMP, EIF2AK2 | DUT 49/4885PKM 1616/4885ALDH1A1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.